GLP-1 Drugs Linked to 21% Higher Daytime Sleepiness Risk
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) act on the brain as well as the gut, and a 2026 real-world cohort study from Kamel-Abusalha et al. propensity-matched 118,993 GLP-1 RA users to 118,993 non-users in the TriNetX network and found a modest but statistically robust 21–23% higher hazard of new-onset hypersomnolence at 1 and 5 years.1 …